insulin glargine/lixisenatide
General
High Alert Medication: This medication bears a heightened risk of causing significant patient harm when it is used in error.
Pronunciation: 
in-soo-lin glar-jeen/lix-i-sen-a-tide
 To hear audio pronunciation of this topic, purchase a subscription or log in.
To hear audio pronunciation of this topic, purchase a subscription or log in.Trade Name(s)
- Soliqua
Ther. Class.
Pharm. Class.
pancreatics
glucagon like peptide 1 glp 1 receptor agonists
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., et al. "Insulin Glargine/lixisenatide." Davis's Drug Guide, 19th ed., F.A. Davis Company, 2025. Medicine Central, im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/110576/6/insulin_glargine_lixisenatide. 
Vallerand AHA, Sanoski CAC,  . Insulin glargine/lixisenatide. Davis's Drug Guide. F.A. Davis Company; 2025. https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/110576/6/insulin_glargine_lixisenatide. Accessed October 31, 2025.
Vallerand, A. H., Sanoski, C. A., & ,  (2025). Insulin glargine/lixisenatide. In Davis's Drug Guide (19th ed.). F.A. Davis Company. https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/110576/6/insulin_glargine_lixisenatide
Vallerand AHA, Sanoski CAC,  . Insulin Glargine/lixisenatide [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2025. [cited 2025 October 31]. Available from: https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/110576/6/insulin_glargine_lixisenatide.
* Article titles in AMA citation format should be in sentence-case
TY  -  ELEC
T1  -  insulin glargine/lixisenatide
ID  -  110576
A1  -  Sanoski,Cynthia A,
AU  -  Vallerand,April Hazard,
AU  -  ,,
BT  -  Davis's Drug Guide
UR  -  https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/110576/6/insulin_glargine_lixisenatide
PB  -  F.A. Davis Company
ET  -  19
DB  -  Medicine Central
DP  -  Unbound Medicine
ER  -  

 Davis's Drug Guide
Davis's Drug Guide

